PressDecember 6, 2022 Enthea Announces Nationwide Rollout to Offer Psychedelic Therapy as a Workplace Benefit
PressDecember 6, 2022 PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio
PressDecember 2, 2022 Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
PressDecember 2, 2022 Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
PressNovember 30, 2022 Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130
PressNovember 30, 2022 GOODMIND™ Available for Sale in the United Kingdom and Europe – Exclusive Distribution Agreement Concluded With This Works
PressNovember 30, 2022 Irwin Naturals Leverages Household Brand Status in Effort to be World’s Largest Chain of Psychedelic Mental Health Clinics
PressNovember 30, 2022 Braxia Scientific Reports Q2 2023 Financial Results; Focused on Growing Clinic and Telemedicine Delivery of Novel Mental Health Treatments in North America
PressNovember 30, 2022 Psyrise Launches the First End-To-End Marketing Platform for Ketamine Clinics, Retreats, and Psychedelic-Assisted Therapists
PressNovember 28, 2022 Field Trip Health & Wellness Ltd. Announces Updated Time for Fiscal Second Quarter 2023 Financial Results and Conference Call
PressNovember 27, 2022 Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
